Kilpatrick Townsend’s Silicon Valley-based start-up team advised the founders of Editas Medicine in the biotech start-up’s $43 million Series A Financing. In a trend setting transaction, venture firms Polaris Partners, Third Rock Ventures, Flagship Ventures and the Partners Innovation Fund invited five of the most prominent research scientists in the field of genomics from MIT, Harvard, the Howard Hughes Medical Institute and the University of California in Berkeley to form a company which they would fund. The money invested will fund the collaborative research and development by this world-class team of scientists as they seek to revolutionize the treatment of genetic disorders by developing a simple, precise and inexpensive method of ‘editing out’ abnormalities in genes in human cells.

Experience Center

Match our Experience to Your Needs

View All Case Studies

Experience Highlights

Contract Dispute Arbitration for a publicly traded supplier of industrial parts
Represented a publicly traded supplier of industrial parts in the successful arbitration of a significant breach of contract dispute against one of more
Patent litigation for subsidiary of Redcats USA

Served as lead counsel on behalf of The Sportsman’s Guide, Inc., a subsidiary of Redcats USA, a leading specialty more

Design, construction, and commissioning of an off-shore oil production facility in Malaysia for worldwide oil and gas organization
Represent a worldwide oil and gas organization with respect to disputes against various EPC contractors retained to perform the design, more
Tax issues relating to biodiesel blending and exporting for largest fuel suppliers in the United Kingdom
Represented one of the largest fuel suppliers in the United Kingdom with complex federal and state tax issues related to its biodiesel blending and more